Methergine is an ergot alkaloid that is a synthetic derivative of ergotamine. It is a potent vasoconstrictor and uterine stimulant, primarily used to control postpartum hemorrhage and to prevent and treat uterine atony. Methergine's synthesis involves chemical modifications of natural ergot alkaloids, typically starting with ergotamine or ergonovine. It exerts its effects by stimulating alpha-adrenergic receptors, leading to uterine contraction and vasoconstriction. Methergine is studied due to its importance in the management of postpartum hemorrhage, a potentially life-threatening condition for both mother and baby. Its vasoconstrictive properties are also explored for their potential therapeutic applications in other conditions, such as migraine headaches. However, methergine's use is associated with significant side effects, including hypertension, nausea, and vomiting. Its application is carefully monitored due to these potential risks.'
| ID Source | ID |
|---|---|
| PubMed CID | 4140 |
| CHEMBL ID | 1597692 |
| CHEBI ID | 91798 |
| SCHEMBL ID | 16092804 |
| MeSH ID | M0013637 |
| Synonym |
|---|
| BRD-A63667919-103-01-9 |
| methergine |
| nsc186067 |
| nsc-186067 |
| mls000756415 , |
| smr000528720 |
| L000928 |
| cas_8226 |
| nsc_8226 |
| bdbm86237 |
| HMS2231B08 |
| HMS3369A11 |
| CHEMBL1597692 |
| SCHEMBL16092804 |
| ergoline-8-carboxamide, 9,10-didehydro-n-[1-(hydroxymethyl)propyl]-6-methyl-, [8.beta.(s)]- |
| ergoline-8.beta.-carboxamide, 9,10-didehydro-n-[(s)-1-(hydroxymethyl)propyl]-6-methyl- |
| methergine (salt/mix) |
| 9,10-didehydro-n-[(s)-1-(hydroxymethyl)propyl]-6-methylergoline-8.beta.-carboxamide |
| methergin (salt/mix) |
| ergoline-8-carboxamide, 9,10-didehydro-n-[(1s)-1-(hydroxymethyl)propyl]-6-methyl-, (8.beta.)- |
| 9,10-didehydro-n-(.alpha.-(hydroxymethyl)propyl)-6-methyl-ergoline-8-.beta.-carboxamide |
| n-[1-(hydroxymethyl)propyl]-6-methyl-9,10-didehydroergoline-8-carboxamide, [8.beta.(s)]- # |
| n-[.alpha.-(hydroxymethyl)propyl]-d-lysergamide |
| UNBRKDKAWYKMIV-UHFFFAOYSA-N |
| CHEBI:91798 |
| Q27163599 |
| n-(1-hydroxybutan-2-yl)-7-methyl-6,6a,8,9-tetrahydro-4h-indolo[4,3-fg]quinoline-9-carboxamide |
| isomethergine |
| DTXSID10859203 |
| 54808-91-2 |
| Class | Description |
|---|---|
| ergoline alkaloid | One of a class of naturally occurring alkaloids with a structure based on that of ergoline. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 8.9125 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 84.2789 | 0.1000 | 20.8793 | 79.4328 | AID588453; AID588456 |
| GLS protein | Homo sapiens (human) | Potency | 35.4813 | 0.3548 | 7.9355 | 39.8107 | AID624170 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 22.3872 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| transcriptional regulator ERG isoform 3 | Homo sapiens (human) | Potency | 50.1187 | 0.7943 | 21.2757 | 50.1187 | AID624246 |
| importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 125.8920 | 5.8048 | 36.1306 | 65.1308 | AID540263 |
| snurportin-1 | Homo sapiens (human) | Potency | 125.8920 | 5.8048 | 36.1306 | 65.1308 | AID540263 |
| peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 39.8107 | 0.4256 | 12.0591 | 28.1838 | AID504891 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 89.1251 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 35.4813 | 0.0041 | 9.9625 | 28.1838 | AID2675 |
| D(3) dopamine receptor isoform e | Homo sapiens (human) | Potency | 2.8184 | 0.0200 | 9.1485 | 39.8107 | AID720506 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 6.3096 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| mu-type opioid receptor isoform MOR-1 | Homo sapiens (human) | EC50 (µMol) | 92.4890 | 0.1320 | 3.3004 | 9.5690 | AID624499 |
| 5-hydroxytryptamine receptor 2A | Mus musculus (house mouse) | EC50 (µMol) | 0.0196 | 0.0038 | 1.3621 | 8.3930 | AID624503 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Caspase 6, apoptosis-related cysteine peptidase | Homo sapiens (human) | AC50 | 27.3300 | 0.0636 | 11.2358 | 44.9700 | AID720632 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (99.41) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||